Ocumetics Technology Corp (TSE:OTC)
:OTC
Top Page
Ocumetics Technology Corp
(OTC)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.53
▼(-2.91% Downside)
Action:UpgradedDate:12/30/25
The score is primarily held down by very weak financial performance (no revenue, ongoing losses, negative equity, and persistent cash burn). Technicals also remain bearish with the stock trading below key moving averages and negative MACD, despite oversold readings. Positive corporate updates around clinical progress and financing provide some support but are not yet reflected in operating fundamentals.
Positive Factors
Clinical progress & near-term funding
Committed financing and early clinical signals materially reduce near-term development execution risk. A ~ $2.9M private placement plus a collaboration to optimize lens delivery supports continued trials and device refinement, helping de-risk regulatory pathways and sustain development momentum over the next several months.
Negative Factors
No revenue / unproven commercialization
The company reports no revenue and sustained multi-million dollar losses, indicating it has not commercialized products. Without operational sales, long-term value depends entirely on clinical and regulatory success, making future cash needs and dilution risk structural constraints on growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical progress & near-term funding
Committed financing and early clinical signals materially reduce near-term development execution risk. A ~ $2.9M private placement plus a collaboration to optimize lens delivery supports continued trials and device refinement, helping de-risk regulatory pathways and sustain development momentum over the next several months.
Read all positive factors
Ocumetics Technology Corp (OTC) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$22.17M
Dividend YieldN/A
Average Volume (3M)77.99K
Price to Earnings (P/E)―
Beta (1Y)0.58
Revenue GrowthN/A
EPS Growth-41.53%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.01
Shares Outstanding53,414,104
10 Day Avg. Volume70,232
30 Day Avg. Volume77,988
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-18.55
Price to Sales (P/S)0.00
P/FCF Ratio-14.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ocumetics Technology Corp Business Overview & Revenue Model
Company Description
Ocumetics Technology Corp., a research and product development company, designs and produces various lenses. Its products include Bionic Lens, an expandable intraocular lens that fits within the natural lens compartment of the eye to eliminate the...
How the Company Makes Money
Ocumetics Technology Corp generates revenue primarily through the development and sale of its proprietary eye care products. The company's main revenue stream comes from the commercialization of its advanced lens technologies, which are sold to he...
Ocumetics Technology Corp Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Jul 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -69.94K | -134.30K | -117.62K | -102.21K | -96.18K | 0.00 |
| EBITDA | -2.85M | -2.29M | -3.50M | -2.09M | -3.42M | -99.35K |
| Net Income | -4.24M | -3.02M | -3.64M | -2.22M | -598.19K | -172.49K |
Balance Sheet | ||||||
| Total Assets | 1.63M | 2.32M | 1.04M | 1.37M | 825.25K | 225.32K |
| Cash, Cash Equivalents and Short-Term Investments | 905.41K | 1.57M | 235.83K | 602.09K | 83.90K | 224.35K |
| Total Debt | 4.92M | 3.95M | 321.64K | 292.34K | 0.00 | 0.00 |
| Total Liabilities | 5.52M | 4.26M | 945.33K | 536.45K | 1.10M | 17.94K |
| Stockholders Equity | -3.88M | -1.94M | 91.10K | 837.40K | -270.50K | 207.38K |
Cash Flow | ||||||
| Free Cash Flow | -2.43M | -2.51M | -2.19M | -1.69M | -213.63K | -817.00 |
| Operating Cash Flow | -2.36M | -2.43M | -2.05M | -1.62M | -89.13K | -817.00 |
| Investing Cash Flow | -109.77K | -1.46M | -142.17K | -66.82K | -214.92K | 0.00 |
| Financing Cash Flow | 1.37M | 3.85M | 1.82M | 444.35K | 387.11K | 0.00 |
Ocumetics Technology Corp Technical Analysis
Neutral
0.55
Price Trends
0.47
Negative
0.59
Negative
0.72
Negative
Market Momentum
-0.01
Negative
48.01
Neutral
69.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OTC, the sentiment is Neutral. The current price of 0.55 is above the 20-day moving average (MA) of 0.42, above the 50-day MA of 0.47, and below the 200-day MA of 0.72, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 48.01 is Neutral, neither overbought nor oversold. The STOCH value of 69.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:OTC.
Ocumetics Technology Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | C$49.71M | 95.68 | 3.31% | ― | 5.29% | -29.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$21.58M | -5.28 | 106.68% | ― | 28.59% | 23.46% | |
46 Neutral | C$21.31M | -29.60 | -31.12% | ― | 9.71% | -118.02% | |
44 Neutral | C$22.17M | -31.01 | ― | ― | ― | -41.53% | |
42 Neutral | C$41.62M | -1.50 | -220.14% | ― | 209.29% | 35.38% |
* Healthcare Sector Average
TSE:OTC
Ocumetics Technology Corp
0.42
0.13
48.21%
TSE:ASG
Aurora Spine
0.27
-0.05
-14.69%
TSE:COV
Covalon Technologies
1.80
-0.37
-17.05%
TSE:PINK
Perimeter Medical Imaging AI
0.33
-0.10
-24.14%
TSE:VPT
VentriPoint Diagnostics
0.12
-0.03
-17.86%
TSE:CNVI
Conavi Medical
0.40
-0.20
-34.17%
Ocumetics Technology Corp Corporate Events
Business Operations and StrategyProduct-Related Announcements
Ocumetics De-Risks Accommodating Lens Platform With Strong First-in-Human Results
Positive
Feb 3, 2026
Ocumetics Technology Corp. reported positive three-month postoperative results from the first group of patients in its first-in-human clinical study of its accommodating intraocular lens, with data meeting or exceeding internal benchmarks for safe...
Business Operations and StrategyPrivate Placements and Financing
Ocumetics Seeks Debenture Forbearance and Warrant Incentive to Extend $4 Million Financing
Neutral
Jan 31, 2026
Ocumetics Technology Corp. has proposed a forbearance agreement with holders of its up to $4 million secured convertible debentures issued in 2024, under which debentureholders would agree not to demand repayment or enforce their security until Ju...
Business Operations and StrategyExecutive/Board Changes
Ocumetics Replaces Chief Medical Officer Role With Scientific Advisory Committee Ahead of Pivotal Trial
Positive
Jan 9, 2026
Ocumetics Technology Corp., a leader in next-generation ophthalmic technology, is restructuring its medical and clinical leadership as it advances its accommodating intraocular lens through early feasibility studies toward late-stage clinical deve...
Business Operations and StrategyPrivate Placements and Financing
Ocumetics Raises Over $1 Million to Advance First-in-Human Clinical Trials
Positive
Jan 2, 2026
Ocumetics Technology Corp. has closed the first tranche of a brokered private placement and a concurrent non-brokered placement, raising total gross proceeds of approximately $1.02 million through the sale of 1,706,383 units at $0.60 per unit, eac...
Business Operations and StrategyPrivate Placements and Financing
Ocumetics Amends Terms of Brokered Financing to Raise Up to $2.9 Million
Positive
Dec 19, 2025
Ocumetics Technology Corp. has amended the terms of its previously announced brokered private placement led by Centurion One Capital, now planning to issue up to 4,166,666 units at $0.60 per unit for gross proceeds of up to $2.5 million, with each...
Business Operations and StrategyProduct-Related Announcements
Ocumetics and Medicel Collaborate on Enhanced Lens Delivery System
Positive
Dec 9, 2025
Ocumetics Technology Corp. has announced an optimized lens delivery system developed in collaboration with Medicel AG, a leader in ophthalmic device delivery systems. This enhancement, based on surgeon feedback from initial human implantations, ai...
Business Operations and StrategyPrivate Placements and Financing
Ocumetics Technology Corp. Launches $2.5 Million Private Placement to Fund Clinical Trials
Positive
Nov 26, 2025
Ocumetics Technology Corp. has announced a brokered private placement led by Centurion One Capital to raise $2.5 million through the sale of units, each consisting of a common share and a warrant. The funds are intended to support the company̵...
Product-Related Announcements
Ocumetics Reports Promising Early Results in Intraocular Lens Study
Positive
Nov 5, 2025
Ocumetics Technology Corp. announced promising one-month results from its first-in-human clinical study of the Ocumetics Accommodating Intraocular Lens. The initial group of patients showed significant improvement in vision, surpassing expectation...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.